All lobbying filings
SPLITOAK STRATEGIES LLC
Lobbying for ALKERMES, INC. · Global biopharmaceutical company
Filing
3rd Quarter - Report
Bills named in this filing
1
Lobbying activity
1
Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments for substance use disorder and alcohol use disorder; Initiatives to promote the use of relapse prevention post detoxification; Advance the use and funding of FDA-approved medicines to treat serious mental illness in criminal justice and public health settings; H.R. 4030, Treatment Continuity Act of 2025